Hadassah Medical Center and Neurogenesis, jointly in progressive multiple sclerosis

NeuroGenesis, a clinical-stage biopharmaceutical company, and Hadassah center announced highly positive results from a placebo-controlled phase 2 clinical test , headed by Prof. Dimitrios Karussis, along side Dr. Petrou Panayiota and Dr. Ibrahim Kassis from Hadassah center in Jerusalem, assessing the impact of NG-01 autologous proprietary subpopulation of mesenchymal stem cells (MSCs) on patients with progressive MS (MS).

The results show no serious, treatment-related questions of safety . Significantly fewer patients experienced treatment failure (disease progression) within the intrathecal (IT) and intravenous (IV) NG-01 treatment groups compared with those within the placebo group (6.7%, 9.7%, and 41.9%, respectively, P = 0.0003 and P = 0.0008); 58% of the patients treated intrathecally with NG-01 didn’t show Any Evidence of Disease Activity (NEDA) during the whole the treatment period (vs 9.7% within the placebo treated group)